Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 278

1.

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.

Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, Shabafrouz K, Ribi C, Cairoli A, Guex-Crosier Y, Kuntzer T, Michielin O, Peters S, Coukos G, Spertini F, Thompson JA, Obeid M.

Nat Rev Clin Oncol. 2019 May 15. doi: 10.1038/s41571-019-0218-0. [Epub ahead of print] Review.

PMID:
31092901
2.

[Side effects of immune checkpoint inhibitors: diagnosis and management].

Perrinjaquet C, Zaher M, Ferraro DA, Comte D, Trueb L, Zimmermann S, Coukos G, Orcurto A.

Rev Med Suisse. 2019 May 15;15(651):1010-1016. French.

PMID:
31091034
3.

High-throughput screening of human tumor-antigen specific CD4 T cells, including neo-antigen reactive T cells.

Costa-Nunes C, Cachot A, Bobisse S, Arnaud M, Genolet R, Baumgaertner P, Speiser DE, Sousa Alves PM, Sandoval F, Adotévi O, Reith W, Protti MP, Coukos G, Harari A, Romero P, Jandus C.

Clin Cancer Res. 2019 Apr 23. pii: clincanres.1356.2018. doi: 10.1158/1078-0432.CCR-18-1356. [Epub ahead of print]

PMID:
31015344
4.

The clinical application of cancer immunotherapy based on naturally circulating dendritic cells.

Bol KF, Schreibelt G, Rabold K, Wculek SK, Schwarze JK, Dzionek A, Teijeira A, Kandalaft LE, Romero P, Coukos G, Neyns B, Sancho D, Melero I, de Vries IJM.

J Immunother Cancer. 2019 Apr 18;7(1):109. doi: 10.1186/s40425-019-0580-6. Review.

5.

Going Beyond the Sequences: TCR Binding Patterns at the Service of Cancer Detection.

Zoete V, Coukos G.

Cancer Res. 2019 Apr 1;79(7):1299-1301. doi: 10.1158/0008-5472.CAN-19-0225.

PMID:
30936076
6.

Correction: Tumour-reactive T cell subsets in the microenvironment of ovarian cancer.

Westergaard MCW, Andersen R, Chong C, Kjeldsen JW, Pedersen M, Friese C, Hasselager T, Lajer H, Coukos G, Bassani-Sternberg M, Donia M, Svane IM.

Br J Cancer. 2019 Apr;120(8):870. doi: 10.1038/s41416-019-0425-6.

PMID:
30890776
7.

Computational KIR copy number discovery reveals interaction between inhibitory receptor burden and survival.

Pyke RM, Genolet R, Harari A, Coukos G, Gfeller D, Carter H.

Pac Symp Biocomput. 2019;24:148-159.

8.

The NAD-Booster Nicotinamide Riboside Potently Stimulates Hematopoiesis through Increased Mitochondrial Clearance.

Vannini N, Campos V, Girotra M, Trachsel V, Rojas-Sutterlin S, Tratwal J, Ragusa S, Stefanidis E, Ryu D, Rainer PY, Nikitin G, Giger S, Li TY, Semilietof A, Oggier A, Yersin Y, Tauzin L, Pirinen E, Cheng WC, Ratajczak J, Canto C, Ehrbar M, Sizzano F, Petrova TV, Vanhecke D, Zhang L, Romero P, Nahimana A, Cherix S, Duchosal MA, Ho PC, Deplancke B, Coukos G, Auwerx J, Lutolf MP, Naveiras O.

Cell Stem Cell. 2019 Mar 7;24(3):405-418.e7. doi: 10.1016/j.stem.2019.02.012.

PMID:
30849366
9.

Tumor Landscapes: β-Catenin Drives Immune Desertification.

Dangaj D, Barras D, Coukos G.

Clin Cancer Res. 2019 May 15;25(10):2943-2945. doi: 10.1158/1078-0432.CCR-19-0188. Epub 2019 Mar 5.

PMID:
30837277
10.

Tumour-reactive T cell subsets in the microenvironment of ovarian cancer.

Westergaard MCW, Andersen R, Chong C, Kjeldsen JW, Pedersen M, Friese C, Hasselager T, Lajer H, Coukos G, Bassani-Sternberg M, Donia M, Svane IM.

Br J Cancer. 2019 Feb;120(4):424-434. doi: 10.1038/s41416-019-0384-y. Epub 2019 Feb 5. Erratum in: Br J Cancer. 2019 Apr;120(8):870.

PMID:
30718808
11.

Safety and Tolerability of Adoptive Cell Therapy in Cancer.

Wolf B, Zimmermann S, Arber C, Irving M, Trueb L, Coukos G.

Drug Saf. 2019 Feb;42(2):315-334. doi: 10.1007/s40264-018-0779-3. Review.

PMID:
30649750
12.

[Recent advances and future directions in CAR-T cell therapy in pediatric oncology].

Ceppi F, Renella R, Diezi M, Ansari M, Duchosal MA, Arber C, Kandalaft L, Coukos G, Beck-Popovic M.

Rev Med Suisse. 2019 Jan 9;15(N° 632-633):85-91. French.

PMID:
30629377
13.

New therapeutic perspectives to manage refractory immune checkpoint-related toxicities.

Martins F, Sykiotis GP, Maillard M, Fraga M, Ribi C, Kuntzer T, Michielin O, Peters S, Coukos G, Spertini F, Thompson JA, Obeid M.

Lancet Oncol. 2019 Jan;20(1):e54-e64. doi: 10.1016/S1470-2045(18)30828-3.

PMID:
30614479
14.

A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy.

Horisberger A, La Rosa S, Zurcher JP, Zimmermann S, Spertini F, Coukos G, Obeid M.

J Immunother Cancer. 2018 Dec 27;6(1):156. doi: 10.1186/s40425-018-0481-0.

15.

Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy.

Maio M, Coukos G, Ferrone S, Fox BA, Fridman WH, Garcia PL, Lahn M, Provendier O, Russo V, Rüttinger D, Shalabi A, Trajanoski Z, Viallet J, Wolchok JD, Ibrahim R.

Cancer Immunol Immunother. 2019 Jan;68(1):1-9. doi: 10.1007/s00262-018-2285-y. Epub 2018 Dec 18.

PMID:
30564889
16.

The Length Distribution and Multiple Specificity of Naturally Presented HLA-I Ligands.

Gfeller D, Guillaume P, Michaux J, Pak HS, Daniel RT, Racle J, Coukos G, Bassani-Sternberg M.

J Immunol. 2018 Dec 15;201(12):3705-3716. doi: 10.4049/jimmunol.1800914. Epub 2018 Nov 14.

PMID:
30429286
17.

A severe case of neuro-Sjögren's syndrome induced by pembrolizumab.

Ghosn J, Vicino A, Michielin O, Coukos G, Kuntzer T, Obeid M.

J Immunother Cancer. 2018 Oct 22;6(1):110. doi: 10.1186/s40425-018-0429-4.

18.

Two-Dimensional Label-Free Affinity Analysis of Tumor-Specific CD8 T Cells with a Biomimetic Plasmonic Sensor.

Soler M, Li X, John-Herpin A, Schmidt J, Coukos G, Altug H.

ACS Sens. 2018 Nov 26;3(11):2286-2295. doi: 10.1021/acssensors.8b00523. Epub 2018 Oct 19.

PMID:
30339020
19.

50-Gy Stereotactic Body Radiation Therapy to the Dominant Intraprostatic Nodule: Results From a Phase 1a/b Trial.

Herrera FG, Valerio M, Berthold D, Tawadros T, Meuwly JY, Vallet V, Baumgartner P, Thierry AC, De Bari B, Jichlinski P, Kandalaft L, Coukos G, Harari A, Bourhis J.

Int J Radiat Oncol Biol Phys. 2019 Feb 1;103(2):320-334. doi: 10.1016/j.ijrobp.2018.09.023. Epub 2018 Sep 27.

20.

Correction to: CART cells are prone to Fas- and DR5-mediated cell death.

Tschumi BO, Dumauthioz N, Marti B, Zhang L, Lanitis E, Irving M, Schneider P, Mach JP, Coukos G, Romero P, Donda A.

J Immunother Cancer. 2018 Sep 25;6(1):92. doi: 10.1186/s40425-018-0410-2.

Supplemental Content

Loading ...
Support Center